Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Endovia Health Sciences and Lupvindol BioSciences' product now eligible for Conditional Approval Pathway
Endovia Health Sciences, Inc. (NYSE: EDVA) and Lupvindol BioSciences announced that the FDA has determined that CannEpil® for canine bone cancer pain qualifies as a minor use. This determination establishes the product's eligibility for the Conditional Approval Pathway.
The FDA's decision is based on the product's intended use and the specific conditions it addresses in canine patients. With this pathway, the companies can proceed with further development and potential approval of CannEpil® for veterinary use.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.